JP7653759B2 - 養子免疫療法における免疫細胞調節のための組成物および方法 - Google Patents

養子免疫療法における免疫細胞調節のための組成物および方法 Download PDF

Info

Publication number
JP7653759B2
JP7653759B2 JP2018537803A JP2018537803A JP7653759B2 JP 7653759 B2 JP7653759 B2 JP 7653759B2 JP 2018537803 A JP2018537803 A JP 2018537803A JP 2018537803 A JP2018537803 A JP 2018537803A JP 7653759 B2 JP7653759 B2 JP 7653759B2
Authority
JP
Japan
Prior art keywords
cells
cell
pge
population
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018537803A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019502725A5 (cg-RX-API-DMAC10.html
JP2019502725A (ja
Inventor
ローゼン,ジョナサン
レズナー,ベッツィ
バラマール,バーラム
ビョーダール,リャン
ペラルタ,アイゲン
ハーディ,イアン
Original Assignee
フェイト セラピューティクス,インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フェイト セラピューティクス,インコーポレイテッド filed Critical フェイト セラピューティクス,インコーポレイテッド
Publication of JP2019502725A publication Critical patent/JP2019502725A/ja
Publication of JP2019502725A5 publication Critical patent/JP2019502725A5/ja
Priority to JP2023000071A priority Critical patent/JP2023036919A/ja
Priority to JP2024219599A priority patent/JP2025038093A/ja
Application granted granted Critical
Publication of JP7653759B2 publication Critical patent/JP7653759B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Reproductive Health (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018537803A 2016-01-20 2017-01-20 養子免疫療法における免疫細胞調節のための組成物および方法 Active JP7653759B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023000071A JP2023036919A (ja) 2016-01-20 2023-01-04 養子免疫療法における免疫細胞調節のための組成物および方法
JP2024219599A JP2025038093A (ja) 2016-01-20 2024-12-16 養子免疫療法における免疫細胞調節のための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662281064P 2016-01-20 2016-01-20
US62/281,064 2016-01-20
US201662402883P 2016-09-30 2016-09-30
US62/402,883 2016-09-30
PCT/US2017/014449 WO2017127755A1 (en) 2016-01-20 2017-01-20 Compositions and methods for immune cell modulation in adoptive immunotherapies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023000071A Division JP2023036919A (ja) 2016-01-20 2023-01-04 養子免疫療法における免疫細胞調節のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2019502725A JP2019502725A (ja) 2019-01-31
JP2019502725A5 JP2019502725A5 (cg-RX-API-DMAC10.html) 2020-02-27
JP7653759B2 true JP7653759B2 (ja) 2025-03-31

Family

ID=59362155

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018537803A Active JP7653759B2 (ja) 2016-01-20 2017-01-20 養子免疫療法における免疫細胞調節のための組成物および方法
JP2023000071A Pending JP2023036919A (ja) 2016-01-20 2023-01-04 養子免疫療法における免疫細胞調節のための組成物および方法
JP2024219599A Pending JP2025038093A (ja) 2016-01-20 2024-12-16 養子免疫療法における免疫細胞調節のための組成物および方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023000071A Pending JP2023036919A (ja) 2016-01-20 2023-01-04 養子免疫療法における免疫細胞調節のための組成物および方法
JP2024219599A Pending JP2025038093A (ja) 2016-01-20 2024-12-16 養子免疫療法における免疫細胞調節のための組成物および方法

Country Status (4)

Country Link
US (2) US11413309B2 (cg-RX-API-DMAC10.html)
EP (1) EP3405568A4 (cg-RX-API-DMAC10.html)
JP (3) JP7653759B2 (cg-RX-API-DMAC10.html)
WO (1) WO2017127755A1 (cg-RX-API-DMAC10.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7653759B2 (ja) 2016-01-20 2025-03-31 フェイト セラピューティクス,インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
AU2017210031C1 (en) * 2016-01-20 2020-11-26 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
EP3417052B1 (en) * 2016-02-16 2023-02-15 Duke University Methods for expanding and differentiating b cells for producing antibody
US11634686B2 (en) 2016-11-01 2023-04-25 Jian Feng Method of producing naive pluripotent stem cells
US11932870B2 (en) 2016-12-05 2024-03-19 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
AU2018219895C1 (en) 2017-02-09 2024-10-03 Indapta Therapeutics, Inc. Engineered Natural Killer (NK) cells and compositions and methods thereof
CN118662615A (zh) 2017-03-15 2024-09-20 浩康生物系统公司 用于造血干细胞移植的组合物和方法
EP3600357A4 (en) 2017-03-31 2021-01-06 The Board of Trustees of the Leland Stanford Junior University METHODS OF TREATING T-LYMPHOCYTE DEPLETION BY INHIBITING OR MODULATING T-LYMPHOCYTE RECEPTOR SIGNALING
KR102382431B1 (ko) * 2017-11-23 2022-04-01 베이징 이터널 머터리얼 테크놀로지 씨오., 엘티디 화합물 및 이를 이용한 유기 전계 발광 소자
CN111556892A (zh) * 2017-12-08 2020-08-18 菲特治疗公司 使用增强的iPSC衍生的效应细胞的免疫疗法
BR112020011017A2 (pt) 2017-12-22 2020-11-17 Fate Therapeutics, Inc. células efetoras imunes intensificadas e uso das mesmas
EP3914267A1 (en) 2018-01-25 2021-12-01 Mia Levite Methods for improved immunotherapy
AU2019243315A1 (en) * 2018-03-29 2020-09-24 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
EP3884041A2 (en) 2018-11-21 2021-09-29 Indapta Therapeutics, Inc. Methods for expansion of natural killer (nk) cell subset and related compositions and methods
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
WO2020123447A1 (en) * 2018-12-11 2020-06-18 The Regents Of The University Of California Compositions and methods for immunotherapies
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
US11697799B2 (en) 2019-04-15 2023-07-11 Ossium Health, Inc. System and method for extraction and cryopreservation of bone marrow
EP3959305A1 (en) 2019-04-26 2022-03-02 Allogene Therapeutics, Inc. Methods of manufacturing allogeneic car t cells
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
US20220213434A1 (en) 2019-05-10 2022-07-07 The Regents Of The University Of California Modified pluripotent cells
EP4045648A4 (en) * 2019-10-15 2023-11-22 The Regents of The University of California Transplanted cell protection via fc sequestration
CN110628717B (zh) * 2019-10-28 2020-10-30 上海科医联创生物科技有限公司 一种浸润性t细胞的培养方法
CN110592016B (zh) * 2019-10-28 2020-10-02 上海科医联创生物科技有限公司 一种特异性t细胞的培养方法
CN114867485A (zh) * 2019-10-31 2022-08-05 全国儿童医院研究所 Cd38敲除的原代和扩增的人nk细胞的生成
JP7805928B2 (ja) 2019-11-26 2026-01-26 ノバルティス アーゲー Cd19及びcd22キメラ抗原受容体及びその使用
JP7879804B2 (ja) * 2019-12-06 2026-06-24 フェイト セラピューティクス,インコーポレイテッド 小化合物を使用するiPSC由来エフェクター免疫細胞の増強
US20230036952A1 (en) * 2020-01-07 2023-02-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods of producing t cell populations using induced pluripotent stem cells
KR20230040337A (ko) 2020-06-19 2023-03-22 페이트 세러퓨틱스, 인코포레이티드 면역요법 사용을 위한 iPSC-유래 이펙터 세포 유형들의 조합
EP4181675A4 (en) 2020-07-18 2024-04-24 Ossium Health, Inc. PERMEATION OF WHOLE VERTEBRATE BODIES WITH A CRYOPRETECTIVE AGENT USING VACUUM-ASSISTED DIFFUSION
WO2022040504A2 (en) * 2020-08-21 2022-02-24 Georgetown University Stem cell-like memory t cells and uses thereof
EP4228406A4 (en) 2020-10-14 2024-11-13 Ossium Health, Inc. SYSTEMS AND METHODS FOR BONE MARROW EXTRACTION AND CRYOPRESERVATION
EP4229183A4 (en) 2020-10-14 2024-12-11 Ossium Health, Inc. Compositions and methods for extraction of mesenchymal stem cells
EP4262831A4 (en) 2020-12-18 2025-01-01 Ossium Health, Inc. CELLULAR THERAPY PROCESSES
CN114763563B (zh) * 2021-01-12 2024-04-30 深圳华大临床检验中心 一种提高慢病毒感染效率的方法
EP4288069A4 (en) * 2021-02-07 2025-03-12 Baylor College of Medicine Engineered nkt cells for expansion and in vivo preservation and methods of use for the control of tumor cells
WO2022254337A1 (en) 2021-06-01 2022-12-08 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
KR20250004622A (ko) 2022-04-08 2025-01-08 페이트 세러퓨틱스, 인코포레이티드 종양 표적화를 위한 키메라 항원 수용체
KR20250005097A (ko) 2022-04-08 2025-01-09 페이트 세러퓨틱스, 인코포레이티드 고형 종양 표적화 골격을 갖는 세포 및 이의 용도
WO2024211852A1 (en) * 2023-04-07 2024-10-10 Fate Therapeutics, Inc. Ipsc-derived nk cell for lymphoma treatment
WO2024243325A2 (en) * 2023-05-22 2024-11-28 The Board Of Trustees Of The University Of Illinois Combination of pac-1 and car t-cell treatments
CN116904400B (zh) * 2023-09-12 2023-12-01 成都以邦医药科技有限公司 可利霉素在体外car/tcr-t细胞产品制备过程优化中的应用
WO2025217183A1 (en) * 2024-04-09 2025-10-16 Board Of Regents, The University Of Texas System Prepared natural killer cells and uses thereof
CN119161336B (zh) * 2024-07-24 2025-09-05 四川大学 一种作为Blimp1抑制剂的小分子化合物及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012515213A (ja) 2009-01-14 2012-07-05 ヘルス リサーチ インコーポレイテッド 免疫応答を増強するための、mTOR阻害剤を含有する方法及び組成物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003455C (en) 1988-11-23 2000-02-22 Craig B. Thompson Immunotherapy involving cd28 stimulation
ES2229515T3 (es) 1997-07-01 2005-04-16 Warner-Lambert Company Llc Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek.
HK1048302A1 (zh) 1999-08-13 2003-03-28 大正制药株式会社 前列腺素衍生物
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20050075276A1 (en) 2003-03-14 2005-04-07 Christopher Rudd Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses
KR101190912B1 (ko) 2003-11-19 2012-10-12 어레이 바이오파마 인크. Mek의 헤테로시클릭 억제제 및 그의 사용 방법
TWI441637B (zh) 2005-05-18 2014-06-21 Array Biopharma Inc Mek雜環抑制劑及其使用方法
WO2007103901A2 (en) 2006-03-06 2007-09-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer
CA2657227A1 (en) 2006-07-14 2008-01-17 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
GB2444853B (en) 2006-12-14 2010-02-24 Medical Res Council Methods & uses
JP5951254B2 (ja) 2008-03-17 2016-07-13 ザ スクリプス リサーチ インスティテュート 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法
CA2728739C (en) 2008-06-20 2017-07-11 Duke University Use of human cytomegalovirus antigens to enhance immune responses to cancer cells
AU2009322346B2 (en) 2008-12-03 2015-07-02 The Scripps Research Institute Stem cell cultures
WO2011159726A2 (en) 2010-06-14 2011-12-22 The Scripps Research Institute Reprogramming of cells to a new fate
JP5897035B2 (ja) 2010-12-14 2016-03-30 ユニバーシティ オブ メリーランド,ボルチモア 汎用の抗タグキメラ抗原受容体発現t細胞及びがんを治療する方法
EP2638896A1 (en) 2012-03-14 2013-09-18 Bioneer A/S Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood
EP3789487A1 (en) 2013-04-03 2021-03-10 Memorial Sloan Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
CA2977839C (en) 2014-02-28 2022-07-26 The Royal Institution For The Advancement Of Learning / Mcgill University Tc-ptp inhibitors as apc activators for immunotherapy
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
RS61406B1 (sr) * 2014-06-06 2021-03-31 Bluebird Bio Inc Poboljšane kompozicije t ćelija
EP3191126B1 (en) 2014-09-13 2020-05-13 Novartis AG Combination therapies of alk inhibitors
CA2974903A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
US10626372B1 (en) 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CA2980592A1 (en) 2015-03-27 2016-10-06 Nantkwest, Inc. Nk-92 cells in combination therapy with cancer drugs
HK1247958A1 (zh) 2015-05-05 2018-10-05 菲特治疗公司 T淋巴细胞的调节
CN107849102B (zh) 2015-05-15 2022-05-13 希望之城 嵌合抗原受体组合物
WO2017040324A1 (en) 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
CN122146606A (zh) 2015-11-04 2026-06-05 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
AU2017210031C1 (en) * 2016-01-20 2020-11-26 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
JP7653759B2 (ja) 2016-01-20 2025-03-31 フェイト セラピューティクス,インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
US11365392B2 (en) * 2016-08-05 2022-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Ex vivo generation of MHCII restricted CD4+ FOXP3+ regulatory T cells and therapeutic uses thereof
JP2019530470A (ja) * 2016-08-05 2019-10-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル γδFoxp3+調節性T細胞のエクスビボ生成及びその治療的使用
US11932870B2 (en) 2016-12-05 2024-03-19 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
EP3638775A1 (en) 2017-06-13 2020-04-22 Fate Therapeutics, Inc. Compositions and methods for inducing myeloid suppressive cells and use thereof
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012515213A (ja) 2009-01-14 2012-07-05 ヘルス リサーチ インコーポレイテッド 免疫応答を増強するための、mTOR阻害剤を含有する方法及び組成物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cellular Immunology, 1981, 61, pp.52-61
J Immunol., 2012年01月01日, 188(1), pp.21-28
J Pharmacol Sci, 2010, 112, pp.1-5

Also Published As

Publication number Publication date
WO2017127755A1 (en) 2017-07-27
US20220401487A1 (en) 2022-12-22
JP2025038093A (ja) 2025-03-18
US20190282618A1 (en) 2019-09-19
US12419870B2 (en) 2025-09-23
EP3405568A4 (en) 2019-12-04
JP2019502725A (ja) 2019-01-31
JP2023036919A (ja) 2023-03-14
US11413309B2 (en) 2022-08-16
EP3405568A1 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
US12419870B2 (en) Compositions and methods for immune cell modulation in adoptive immunotherapies
US12281329B2 (en) Compositions and methods for immune cell modulation in adoptive immunotherapies
US20240263135A1 (en) Compositions and methods for immune cell modulation in adoptive immunotherapies
US12036241B2 (en) Compositions and methods for immune cell modulation in adoptive immunotherapies
WO2022059780A1 (ja) iPS細胞を介する再生T細胞の製造方法
HK40092133A (en) Compositions and methods for immune cell modulation in adoptive immunotherapies
HK1253869A1 (en) Compositions and methods for immune cell modulation in adoptive immunotherapies
HK1253869B (en) Compositions and methods for immune cell modulation in adoptive immunotherapies
HK40018398B (en) Compositions and methods for inducing myeloid suppressive cells and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210803

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220307

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220606

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220902

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230104

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230104

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230208

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230228

C092 Termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C092

Effective date: 20230301

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230301

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230414

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250318

R150 Certificate of patent or registration of utility model

Ref document number: 7653759

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150